Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.65 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21535761 | 0.91 | CTSS (0.62) | CARM1PRMT6MAOAMAOBCTSL | |
| SCHEMBL12049826 | 0.91 | CTSS (0.62) | CARM1PRMT6MAOAMAOBCTSL | |
| SCHEMBL9388165 | 0.89 | SLC18A3 (0.58) | CARM1PRMT6 | |
| SCHEMBL12830609 | 0.84 | MAOB (0.63) | CARM1PRMT6MAOAMAOB | |
| SCHEMBL29381887 | 0.84 | CCR3 (0.75) | CARM1PRMT6MAOAMAOB | |
| SCHEMBL23022734 | 0.82 | CARM1 (0.57) | CARM1PRMT6MAOAMAOBCTSL | |
| SCHEMBL24069045 | 0.82 | CARM1 (0.66) | CARM1PRMT6MAOAMAOB | |
| SCHEMBL23026277 | 0.82 | MAOB (0.47) | CARM1PRMT6MAOAMAOB | |
| SCHEMBL23183592 | 0.82 | LMNA (0.50) | CARM1PRMT6MAOAMAOB | |
| SCHEMBL24493162 | 0.82 | NCF1 (0.47) | CARM1PRMT6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347763-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | ATHENEX, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-1778236-B1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347763-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, PAICS, UGT2B7 | CARM1 1070/4885PRMT6 2440/4885MAOA 593/4885 |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, TYMS | CARM1 2197/4885PRMT6 2307/4885MAOA 4118/4885 |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | CARM1 1836/4885PRMT6 2653/4885MAOA 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.